Journal of Neuroimmune Pharmacology

, Volume 2, Issue 3, pp 259–264 | Cite as

CD200–CD200R Regulation of Microglia Activation in the Pathogenesis of Parkinson’s Disease

  • Xi-Jin Wang
  • Min Ye
  • Yu-Hong Zhang
  • Sheng-Di ChenEmail author
Invited Review


The role of CD200–CD200R signaling in immune regulation of the central nervous system has become a popular field of research in recent years. Many studies have shown that there is a close correlation between CD200–CD200R, microglia activation, and Parkinson’s disease (PD). This review discusses the above relationship, highlighting (1) the gene mapping and molecular structure of CD200 and CD200R, (2) the distribution and expression of CD200 and CD200R in the nervous system, (3) the effect of CD200–CD200R signaling on microglia activation, and (4) the role of microglia activation in the pathogenesis and progression of PD. Finally, we discuss the status of current studies on the regulation of microglia activation in PD and strongly suggest that it is very promising to regulate microglia activation in PD via targeting CD200–CD200R signaling pathways.


CD200–CD200R microglia activation Parkinson’s disease 



This work was granted by the National Program of Basic Research (2006cb500706) of China, the National Natural Science Fund (30570637, 30471918), Shanghai Key Project of Basic Science Research (04DZ14005), and Program for Outstanding Medical Academic Leader (LJ 06003).


  1. Arimoto T, Choi DY, Lu X, Liu M, Nguyen XV, Zheng N, Stewart CA, Kim HC, Bing G (2006) Interleukin-10 protects against inflammation-mediated degeneration of dopaminergic neurons in substantia nigra. Neurobiol Aging (in press)Google Scholar
  2. Bamberger ME, Harris ME, McDonald DR, Husemann J, Landreth GE (2003) A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. J Neurosci 23:2665–2674PubMedGoogle Scholar
  3. Banerjee D, Dick AD (2004) Blocking CD200–CD200 receptor axis augments NOS-2 expression and aggravates experimental autoimmune uveoretinitis in Lewis rats. Ocul Immunol Inflamm 12:115–125PubMedCrossRefGoogle Scholar
  4. Barclay AN (1981) Different reticular elements in rat lymphoid tissue identified by localization of Ia, Thy-1 and MRC OX 2 antigens. Immunology 44:727–736PubMedGoogle Scholar
  5. Barclay AN, Ward HA (1982) Purification and chemical characterisation of membrane glycoproteins from rat thymocytes and brain, recognised by monoclonal antibody MRC OX 2. Eur J Biochem 129:447–458PubMedCrossRefGoogle Scholar
  6. Bartolome MV, Ibanez-Olias MA, Gil-Loyzaga P (2002) Transitional expression of OX-2 and GAP-43 glycoproteins in developing rat cochlear nerve fibers. Histol Histopathol 17:83–95PubMedGoogle Scholar
  7. Basu A, Krady JK, Enterline JR, Levison SW (2002) Transforming growth factor beta1 prevents IL-1beta-induced microglial activation, whereas TNFalpha- and IL-6-stimulated activation are not antagonized. Glia 40:109–120PubMedCrossRefGoogle Scholar
  8. Berman ME, Muller WA (1995) Ligation of platelet/endothelial cell adhesion molecule 1 (PECAM-1/CD31) on monocytes and neutrophils increases binding capacity of leukocyte CR3 (CD11b/CD18). J Immunol 154:299–307PubMedGoogle Scholar
  9. Block ML, Hong JS (2005) Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 76:77–98PubMedCrossRefGoogle Scholar
  10. Broderick C, Hoek RM, Forrester JV, Liversidge J, Sedgwick JD, Dick AD (2002) Constitutive retinal CD200 expression regulates resident microglia and activation state of inflammatory cells during experimental autoimmune uveoretinitis. Am J Pathol 161:1669–1677PubMedGoogle Scholar
  11. Bukovsky A, Presl J, Zidovsky J, Mancal P (1983) The localization of Thy-1.1, MRC OX 2 and Ia antigens in the rat ovary and fallopian tube. Immunology 48:587–596PubMedGoogle Scholar
  12. Chen S, Le WD, Xie WJ, Alexianu ME, Engelhardt JI, Siklos L, Appel SH (1998) Experimental destruction of substantia nigra initiated by Parkinson disease immunoglobulins. Arch Neurol 55:1075–1080PubMedCrossRefGoogle Scholar
  13. Deckert M, Sedgwick JD, Fischer E, Schluter D (2006) Regulation of microglial cell responses in murine toxoplasma encephalitis by CD200/CD200 receptor interaction. Acta Neuropathol (Berl) 111:548–558CrossRefGoogle Scholar
  14. Delgado M, Ganea D (2003) Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson’s disease by blocking microglial activation. FASEB J 17:944–946PubMedGoogle Scholar
  15. Di Monte DA (2003) The environment and Parkinson’s disease: is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol 2:531–538PubMedCrossRefGoogle Scholar
  16. Frank MG, Barrientos RM, Biedenkapp JC, Rudy JW, Watkins LR, Maier SF (2006) mRNA up-regulation of MHC II and pivotal pro-inflammatory genes in normal brain aging. Neurobiol Aging 27:717–722PubMedCrossRefGoogle Scholar
  17. Gao HM, Hong JS, Zhang W, Liu B (2002a) Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 22:782–790PubMedGoogle Scholar
  18. Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B (2002b) Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson’s disease. J Neurochem 81:1285–1297PubMedCrossRefGoogle Scholar
  19. Gao HM, Hong JS, Zhang W, Liu B (2003a) Synergistic dopaminergic neurotoxicity of the pesticide rotenone and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson’s disease. J Neurosci 23:1228–1236PubMedGoogle Scholar
  20. Gao HM, Liu B, Zhang W, Hong JS (2003b) Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson’s disease. FASEB J 17:1957–1959PubMedGoogle Scholar
  21. Gao HM, Liu B, Zhang W, Hong JS (2003c) Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson’s disease. FASEB J 17:1954–1956PubMedGoogle Scholar
  22. Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, Eggert K, Oertel W, Banati RB, Brooks DJ (2006) In vivo imaging of microglial activation with ((11)C)(R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis 21:404–412PubMedCrossRefGoogle Scholar
  23. Gorczynski RM, Chen Z, Clark DA, Kai Y, Lee L, Nachman J, Wong S, Marsden P (2004a) Structural and functional heterogeneity in the CD200R family of immunoregulatory molecules and their expression at the feto-maternal interface. Am J Reprod Immunol 52:147–163PubMedCrossRefGoogle Scholar
  24. Gorczynski R, Chen Z, Kai Y, Lee L, Wong S, Marsden PA (2004b) CD200 is a ligand for all members of the CD200R family of immunoregulatory molecules. J Immunol 172:7744–7749PubMedGoogle Scholar
  25. Gorczynski RM (2005) CD200 and its receptors as targets for immunoregulation. Curr Opin Investig Drugs 6:483–488PubMedGoogle Scholar
  26. Hatherley D, Barclay AN (2004) The CD200 and CD200 receptor cell surface proteins interact through their N-terminal immunoglobulin-like domains. Eur J Immunol 34:1688–1694PubMedCrossRefGoogle Scholar
  27. He Y, Appel S, Le W (2001) Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res 909:187–193PubMedCrossRefGoogle Scholar
  28. Hoek RM, Ruuls SR, Murphy CA, Wright GJ, Goddard R, Zurawski SM, Blom B, Homola ME, Streit WJ, Brown MH, Barclay AN, Sedgwick JD (2000) Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 290:1768–1771PubMedCrossRefGoogle Scholar
  29. Ilan N, Madri JA (2003) PECAM-1: old friend, new partners. Curr Opin Cell Biol 15:515–524PubMedCrossRefGoogle Scholar
  30. Jenmalm MC, Cherwinski H, Bowman EP, Phillips JH, Sedgwick JD (2006) Regulation of myeloid cell function through the CD200 receptor. J Immunol 176:191–199PubMedGoogle Scholar
  31. Jones LL, Kreutzberg GW, Raivich G (1998) Transforming growth factor beta’s 1, 2 and 3 inhibit proliferation of ramified microglia on an astrocyte monolayer. Brain Res 795:301–306PubMedCrossRefGoogle Scholar
  32. Kim YS, Joh TH (2004) Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson’s disease. Exp Mol Med 38:333–347Google Scholar
  33. Kim WG, Mohney RP, Wilson B, Jeohn GH, Liu B, Hong JS (2000) Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci 20:6309–6316PubMedGoogle Scholar
  34. Lawson LJ, Perry VH, Dri P, Gordon S (1990) Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 39:151–170PubMedCrossRefGoogle Scholar
  35. Le W, Rowe D, Xie W, Ortiz I, He Y, Appel SH (2001) Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson’s disease. J Neurosci 21:8447–8855PubMedGoogle Scholar
  36. Li R, Huang YG, Fang D, Le WD (2004) (−)-Epigallocatechin gallate inhibits lipopolysaccharide-induced microglial activation and protects against inflammation-mediated dopaminergic neuronal injury. J Neurosci Res 78:723–731PubMedCrossRefGoogle Scholar
  37. Liu B, Du L, Hong JS (2000a) Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J Pharmacol Exp Ther 293:607–617Google Scholar
  38. Liu B, Jiang JW, Wilson B, Du L, Yang SN, Wang JY, Wu GC, Cao XD, Hong JS (2000b) Systemic infusion of naloxone reduces degeneration of rat substantia nigral dopaminergic neurons induced by intranigral injection of lipopolysaccharide. J Pharmacol Exp Ther 295:125–132Google Scholar
  39. Liu B, Gao HM, Hong JS (2003a) Parkinson’s disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation. Environ Health Perspect 111:1065–1073Google Scholar
  40. Liu B, Hong JS (2003b) Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther 304:1–7CrossRefGoogle Scholar
  41. Liu Y, Qin L, Li G, Zhang W, An L, Liu B, Hong JS (2003c) Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. J Pharmacol Exp Ther 305:212–218CrossRefGoogle Scholar
  42. Lu X, Bing G, Hagg T (2000) Naloxone prevents microglia-induced degeneration of dopaminergic substantia nigra neurons in adult rats. Neuroscience 97:285–291PubMedCrossRefGoogle Scholar
  43. Morris RJ, Beech JN (1987) Sequential expression of OX2 and Thy-1 glycoproteins on the neuronal surface during development. An immunohistochemical study of rat cerebellum. Dev Neurosci 9:33–44PubMedGoogle Scholar
  44. Nathan C, Muller WA (2001) Putting the brakes on innate immunity: a regulatory role for CD200? Nat Immunol 2:17–19PubMedCrossRefGoogle Scholar
  45. Newman PJ (1997) The biology of PECAM-1. J Clin Invest 99:3–8PubMedCrossRefGoogle Scholar
  46. Orth M, Tabrizi SJ (2003) Models of Parkinson’s disease. Mov Disord 18:729–737PubMedCrossRefGoogle Scholar
  47. Purisai MG, McCormack AL, Cumine S, Li J, Isla MZ, Di Monte DA (2007) Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration. Neurobiol Dis 25:392–400PubMedCrossRefGoogle Scholar
  48. Qian L, Block ML, Wei SJ, Lin CF, Reece J, Pang H, Wilson B, Hong JS, Flood PM (2006) Interleukin-10 protects lipopolysaccharide-induced neurotoxicity in primary midbrain cultures by inhibiting the function of NADPH oxidase. J Pharmacol Exp Ther 319:44–52PubMedCrossRefGoogle Scholar
  49. Siglienti I, Chan A, Kleinschnitz C, Jander S, Toyka KV, Gold R, Stoll G (2007) Downregulation of transforming growth factor-beta2 facilitates inflammation in the central nervous system by reciprocal astrocyte/microglia interactions. J Neuropathol Exp Neurol 66:47–56PubMedGoogle Scholar
  50. Sugama S, Yang L, Cho BP, DeGiorgio LA, Lorenzl S, Albers DS, Beal MF, Volpe BT, Joh TH (2003) Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice. Brain Res 964:288–294PubMedCrossRefGoogle Scholar
  51. Vieites JM, de la Torre R, Ortega MA, Montero T, Peco JM, Sanchez-Pozo A, Gil A, Suarez A (2003) Characterization of human cd200 glycoprotein receptor gene located on chromosome 3q12–13. Gene 311:99–104PubMedCrossRefGoogle Scholar
  52. Wang XJ, Chen SD, Ma GZ, Ye M, Lu GX (2005a) Genistein protects dopaminergic neurons by inhibiting microglial activation. Neuroreport 16:267–270PubMedCrossRefGoogle Scholar
  53. Wang XJ, Chen SD, Ma GZ, Ye M, Lu GZ (2005b) Involvement of proinflammatory factors, apoptosis, caspase-3 activation and Ca2+ disturbance in microglia activation-mediated dopaminergic cell degeneration. Mech Ageing Dev 126:1241–1254PubMedCrossRefGoogle Scholar
  54. Wang XJ, Yan ZQ, Lu GQ, Stuart S, Chen SD (2007) Parkinson disease IgG and C5a-induced synergistic dopaminergic neurotoxicity: role of microglia. Neurochem Int 50:39–50PubMedCrossRefGoogle Scholar
  55. Webb M, Barclay AN (1984) Localisation of the MRC OX-2 glycoprotein on the surfaces of neurones. J Neurochem 43:1061–1067PubMedCrossRefGoogle Scholar
  56. Wojtera M, Sikorska B, Sobow T, Liberski PP (2005) Microglial cells in neurodegenerative disorders. Folia Neuropathol 43:311–321PubMedGoogle Scholar
  57. Wright GJ, Puklavec MJ, Willis AC, Hoek RM, Sedgwick JD, Brown MH, Barclay AN (2000) Lymphoid/neuronal cell surface OX2 glycoprotein recognizes a novel receptor on macrophages implicated in the control of their function. Immunity 13:233–242PubMedCrossRefGoogle Scholar
  58. Wright GJ, Jones M, Puklavec MJ, Brown MH, Barclay AN (2001) The unusual distribution of the rat lymphoid/neuronal OX2 glycoprotein is conserved in humans (CD200). Immunology 102:173–179PubMedCrossRefGoogle Scholar
  59. Wright GJ, Cherwinski H, Foster-Cuevas M, Brooke G, Puklavec MJ, Bigler M, Song Y, Jenmalm M, Gorman D, McClanahan T, Liu MR, Brown MH, Edgwick JD, Phillips JH, Barclay AN (2003) Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J Immunol 171:3034–3046PubMedGoogle Scholar
  60. Zhang S, Cherwinski H, Sedgwick JD, Phillips JH (2004) Molecular mechanisms of CD200 inhibition of mast cell activation. J Immunol 173:6786–6793PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Xi-Jin Wang
    • 1
  • Min Ye
    • 1
  • Yu-Hong Zhang
    • 1
  • Sheng-Di Chen
    • 1
    • 2
    Email author
  1. 1.Department of Neurology & Institute of Neurology, Rui-Jin HospitalShanghai Jiaotong University School of MedicineShanghaiPeople’s Republic of China
  2. 2.Lab of Neurodegenerative Diseases, Institute of Health Science, Shanghai Institutes of Biological SciencesChinese Academy of Science and Shanghai Jiaotong University School of MedicineShanghaiPeople’s Republic of China

Personalised recommendations